Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home

Juliane Bernholz

CEO

AM-Pharma

Utrecht, Netherlands

34 profile visits

Dr. Juliane Bernholz is a CEO and cell biologist with 30+ years in pharma. As CEO of AM-Pharma, she leads rare disease innovation. Formerly at J&J, Sanofi, Novartis, Actelion she has driven drug development and global collaborations.

My organisation

AM-Pharma

AM-Pharma

SME

Utrecht, Netherlands

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our proprietary compound, ilofotase alfa, is being developed as a potential enzyme replacement therapy for adult hypophosphatasia (HPP) patients. In a Phase 1b clinical proof of concept study in adult HPP patients, ilofotase alfa showed a pronounced effect on all HPP disease-specific biomarkers and normalized alkaline phosphatase activity levels. There were no safety concerns with ilofotase alfa in this study, consistent with previous clinical studies with ilofotase alfa in other indications involving about 1000 patients. These data support its further development as a treatment option for adult HPP patients who are currently underserved. We are a dedicated team driven to bring treatment options to patients in need, their families and healthcare professionals.
Read more

About me

Dr. Juliane Bernholz is an experienced CEO, cell biologist, and molecular geneticist with over 30 years of leadership experience in the pharmaceutical industry having worked and lived in the US and multiple countries in Europe. Currently, she serves as the CEO of AM-Pharma in Utrecht, where she has been instrumental in developing innovative treatments for rare and critical care diseases, including Hypophosphatasia and Acute Kidney Injury. Prior to Dr. Bernholz’ role at AM-Pharma, she held senior leadership positions in R&D and Business Development at renowned companies such as Johnson&Johnson, Sanofi, Novartis and Actelion Pharmaceuticals.

Throughout her career, Dr. Bernholz has successfully led cross-functional teams, managed complex drug development programs, and driven strategic initiatives across small molecules, biologics, new modalities and cutting-edge therapies and has played a key role in bringing multiple therapies to market. Furthermore she has successfully negotiated, executed and chaired collaborations with industry and academia.

With a strong foundation in scientific research, having worked under Nobel laureates and completed a PhD in Cell Biology, Dr. Bernholz is passionate about leveraging scientific innovation to improve patient outcomes. She has completed executive leadership programs at Wharton and IMD including a Board Director Diploma.

Social media